Leadership Transition - Faith Zaslavsky has been appointed as the new CEO of IMAC Holdings, succeeding Jeff Ervin, to lead the company's newly acquired assets in the proteomics and precision medicine industry [1] - The board of directors will now consist of three independent members, following the resignation of co-founders Dr. Matt Wallis and Mr. Ervin, who will serve as a transition consultant [3] Executive Background - Ms. Zaslavsky has 23 years of experience in the genomic space, previously serving as COO and CEO at Theralink Technologies and as President of Oncology for Myriad Genetics, overseeing various commercial functions [2] - Her expertise includes leading teams, designing solutions for physicians, and advocating for cancer patients [2] Technology and Innovation - IMAC has acquired RPPA technology, which has shown through clinical trials to be a superior indicator of key biomarkers for drug selection in breast cancer and other cancers [3] - The company aims to establish RPPA as an essential test for breast cancer patients and other conditions in the near future [3] Company Overview - IMAC Holdings, Inc. focuses on innovative medical advancements in oncology and neurology, utilizing a patented phosphoprotein and protein biomarker platform [4] - The company's lab-developed tests (LDTs) assist oncologists in delivering targeted treatment plans for patients with advanced breast cancer [4]
IMAC Holdings Announces Leadership Succession